UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Identify scenarios where active funds may outperform, focusing on market environments, fees, and your risk tolerance.
14,457 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Meta vs Alphabet in 2026 shapes a critical decision for many investors. This guide breaks down the core factors, offe...
SpaceX IPO chatter has investors itching for early exposure. This guide breaks down the smartest, legally sound ways ...
Lucid represents a high-risk, high-reward bet in the EV space. Before you consider investing, these three practical f...
Researchers report clues that AI seems turn marxist after heavy workloads, raising questions for workers and investor...
A clear look at Copart's 2026 earnings outlook, the drivers behind revenue, and what this could mean for investors. R...
When geopolitics collide with global manufacturing, one top EV maker shows how to turn risk into growth. This story d...
A 50-year-old couple with $1.1 million in retirement savings faces 15 years of growth and withdrawals. With $50,000 s...
A former lineman took a leap during the pandemic and built a $50 million knife company from a backyard workshop. The ...
As AI hype climbs, one tech stock think more could offer substantial upside in the S&P 500. This article lays out the...
Retirees are turning to a simple, low-cost income strategy: a 50/50 blend of municipal bonds and dividend equities to...
A cautious retirement strategy uses an eight-rung treasury bond ladder to aim for about $40,000 a year in stable inco...